Drugs and Therapeutics (D & T) Committee Drugs Under Review for: June 2, 2010
Drug Name | Review Type | Class | Manufacturer |
---|---|---|---|
Victoza | New Drug Initial Review | GLP-1 Receptor Agonist | Novo Nordisk |
Kalbitor | New Drug Initial Review | Orphan Biologic � for HAE | Dyax |
Intuniv | New Drug Initial Review | ADHD Agents | Shire |
Fanapt | New Drug Initial Review | Atypical Antipsychotic | Novartis |
Effient | New Drug Initial Review | Platelet Aggregation Inhibitor | Eli Lilly |
Ampyra | New Drug Initial Review | Multiple Sclerosis Agents | Acorda |
Xifaxan 550 | New Drug Initial Review | Antibiotic | Salix |
Cayston | New Drug Initial Review | Antibiotic | Gilead |
Renvela | New Drug Appeal | Phosphate Binder | Genzyme |
Byetta | New Drug Appeal | GLP-1 Receptor Agonist | Amylin |
Invega Sustenna | New Drug Appeal | Atypical Antipsychotic | Ortho McNeil Janssen |
Multaq | New Drug Appeal | Antiarrhythmic | Sanofi |
Twynsta | New Drug Appeal | Antihypertensive Combination | Boehringer Ingelheim |
Zemplar | New Drug Appeal | Hyperparathyroidism due to CKD | Abbott |
Toviaz | New Drug Appeal | Urinary Anti-Incontinence | Pfizer |
Vivitrol | New Drug Appeal | Opioid Antagonist | Alkermes |